Funding opportunities and RFIs to support research relating to COVID-19 from various agencies/organizations are listed below; please note that this list is not exhaustive. The list will be updated Mondays, Wednesdays, and Fridays by 5 pm. Please contact [email protected] to add a funding opportunity or with any questions.
Proposals for critical continuing laboratory research at Brown that could impact the diagnosis or treatment of COVID-19 in the current crisis should be sent to [email protected] for review and approval.
Solicits community-engaged research to: 1) evaluate intervention strategies (e.g., expand reach, access) to facilitate vaccination (including for COVID-19) uptake in clinical and community contexts; and 2) address the barriers to increasing reach, access, and uptake of vaccinations among health disparity populations at high risk and likely to experience vaccine hesitancy. Apply via PA-20-183 or PA-20-185.
up to $100,000 for studies lasting for between 6-12 months
Computation, Social Sciences, Public Health
Addresses major questions about how to reduce the harm of COVID-19 and future pandemics by uniting data and developing processes, analytical tools and infrastructure to achieve rapid scientific progress and impact.
Biomedical, Clinical Research, Technology Development
Seeks highly collaborative, multi-disciplinary Program Projects that incorporate understanding of CoV virology and immunology, immunogen design, and innovative vaccine and adjuvant platforms and technologies to discover, design, and develop pan-coronavirus (pan-CoV) vaccine candidates that provide broad protective immunity to multiple CoV strains. Apply via PAR-20-072.
Supports research on the effects of smoking or vaping tobacco or marijuana on the risk of acquiring COVID-19 and the clinical course of the infection. Apply via PA-20-183 (R01), PA-20-200 (R03), or PA-20-195 (R21).
To support research on the 2019 novel coronavirus (SARS-CoV-2) and the disease it causes; particularly projects that repurpose existing drugs or biologics (existing therapeutics) that have already begun or completed a Phase I clinical trial. Apply via PAR-17-465 (UG3/UH3), PAR-18-462 (U34), PAR-18-332 (U01).
Encourages applications in three areas related to the intersection of COVID-19, the associated mitigation actions, and rehabilitation: research to address the rehabilitation needs of survivors of COVID-19; understand the impact of disruptions to rehabilitation services caused by the COVID-19 pandemic and associated mitigation actions; understand the social, behavioral, economic, and health impact of the COVID-19 pandemic and the associated mitigation actions on people with physical disabilities. Apply via PA-20-185 (R01), PA-18-480 (R01), PA-20-200 (R03), or PA-20-194 (R21).
Invites applications proposing cutting-edge research on emerging viral infections that are thought to primarily impact non-reproductive sites, at least at initial presentation, but may also affect the male and/or female reproductive tract. Investigate possible effects of emerging viruses on reproductive tissues and cells to better understand potential impacts on fertility that may be sex specific. Apply via PA-20-185 or PA-18-482.
Encourages cooperative agreement applications for implementation of investigator-initiated high-risk clinical trials that will augment ongoing and planned clinical trials of therapeutic and vaccine candidates directed against SARS-CoV-2 to evaluate: SARS-CoV-2 candidate vaccines; non-vaccine biomedical prevention of SARS-CoV-2 infection and/or COVID-19; therapeutic approaches to treat COVID-19. Apply via PAR-18-633.
Biomedical, Clinical Research, Social Sciences, Public Health
This addition to NOT-OD-20-048 seeks to fund investigations of the risk factors associated with COVID-19 disease prevalence among NIH-designated health disparity populations and various categories of women; intersectional and community-based research; and research to assess social and behavioral processes that affect SARS-CoV-2 infection vulnerability and disease severity in underrepresented, understudied, and underreported (U3) populations. Apply via PA-18-591.
Invites applications to repurpose existing therapeutic agents to treat Coronavirus Disease 2019 (COVID-19) sequelae and associated complications that result from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections
NIAID is allowing the submission of applications for Competitive Revisions to active grants to increase and enhance select research efforts to facilitate the Federal SARS-CoV-2/COVID-19 research response. Areas of interest are limited to: Support to BSL3 facilities actively engaged in the SARS-CoV-2/COVID-19 research response; Generation of critical reagents to support the SARS-CoV-2/COVID-19 research response; Expansion of relevant data systems to expeditiously share SARS-CoV-2/COVID-19 research resources with the broad research community; Expansion of clinical trial infrastructure, or site preparation, for urgent SARS-CoV-2/COVID-19 clinical trial activities. See the NOSI for details; apply via PA-20-135
Focuses on the role and impact of digital health interventions [e.g., mobile health (mhealth), telemedicine and telehealth, health information technology (IT), and wearable devices] to address access, reach, delivery, effectiveness, scalability and sustainability of health assessments and interventions for secondary effects (e.g., behavioral health or self-management of chronic conditions) that are utilized during and following the pandemic, particularly in populations who experience health disparities and vulnerable populations
Invites applications for implementation of investigator-initiated multi-site clinical trials (all phases or stages) of interventions focused on specific aging-related issues to reducing transmission, risk, morbidity, mortality, severity, or complications of Coronavirus Disease 2019 (COVID-19)
NCI anticipates that in infrequent cases, NCI-funded investigators will have novel insights and research proposals of immediate relevance to SARS-CoV-2 and COVID-19. In those cases, but only for the duration of the present crisis, NCI would consider requests from its funded grantees and cooperative agreement awardees to engage in limited COVID-19 related research using part of their existing NCI-funded resources.
Remote Access, in-kind Lab labor; not a monetary grant
Biomedical, Clinical Research
Oak Ridge National Laboratory (ORNL) is currently restricting site access. Rapid Access proposals will be performed as remote access experiments with limited internal staff. The Department of Energy Basic Energy Sciences advanced neutron sources will provide remote rapid access to advanced user facilities to support research into the COVID-19 virus and the search for effective diagnostics and therapies. Facilities that will be made available at the Spallation Neutron Source (SNS) and High Flux Isotope Reactor (HFIR) at ORNL , include neutron macromolecular crystallography, small-angle scattering, reflectometry, spectroscopy and imaging beamlines.
Urgent competitive revisions and administrative supplements to existing grants to assess the impact of alcohol as a biological contributor to COVID-19 outcomes, to assess behavioral, social, and economic consequences of the pandemic and to assess the responses that the pandemic has provoked as they relate to alcohol consumption and related outcomes. Apply via PA-18-935 or PA-18-591.
Strengthen the mental health response to COVID-19 and to future public health emergencies; research addressing the intersection of COVID-19, mental health, and HIV treatment and prevention. Apply via PA-18-935 or PA-18-591.
Impact of the novel Coronavirus pandemic causing COVID-19 disease outbreaks and the resulting disruptions on individual and social wellbeing, health services use, and health outcomes for NIH-designated health disparity populations. Apply via PA-18-935 or PA-18-591.
Impact of environmental exposures on COVID-19; the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies. Apply via PA-20-135.
NIA & NIMH are offering Supplements & Revisions to certain active grants. NIA: improve prevention of disease transmission among older adults and mitigation of disease severity and mortality in older adults with COVID-19. NIMH: examine how a disrupted workforce may adequately respond/adapt to and maintain services or provide additional care for new or worsening mental health needs and/or suicide risk in midlife and older age adults. Apply via PA-18-935 or PA-18-591.
Google is offering Google Cloud credits for researchers to leverage their computing capabilities and infrastructure as they study potential therapies and vaccines, track critical data, and identify new ways to combat COVID-19
Biomedical, Clinical Research, Technology development
The U.S. government is providing a portal for the 2019 novel coronavirus (COVID-19) medical countermeasures task force as a single point of entry for the submission of ideas and information regarding diagnostics, therapeutics, vaccines, and other products or technologies relevant to addressing this outbreak.
The DARPA technical offices that are focused on COVID-19 efforts are the Defense Sciences Office (DSO) and the Biological Technology Office (BTO), both of which have Office-Wide Broad Agency Announcements (BAA) that are open for the submission of new ideas at any time.